NantHealth (NASDAQ:NH) was downgraded by analysts at ValuEngine from a sell rating to a strong sell rating in a report issued on Tuesday, January 14th, ValuEngine reports.

Separately, Zacks Investment Research downgraded shares of NantHealth from a buy rating to a hold rating in a research note on Thursday, December 19th.

Shares of NantHealth stock opened at $1.83 on Tuesday. The firm has a market cap of $204.65 million, a P/E ratio of -2.01 and a beta of 1.52. NantHealth has a twelve month low of $0.45 and a twelve month high of $2.75. The firms 50-day simple moving average is $1.17 and its 200-day simple moving average is $0.83.

NantHealth (NASDAQ:NH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.15) EPS for the quarter, missing the Zacks consensus estimate of ($0.07) by ($0.08). The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $23.40 million. NantHealth had a negative net margin of 105.82% and a negative return on equity of 10,106.10%. Sell-side analysts predict that NantHealth will post -0.46 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Paloma Partners Management Co grew its holdings in NantHealth by 436.1% during the second quarter. Paloma Partners Management Co now owns 91,100 shares of the companys stock valued at $48,000 after purchasing an additional 74,108 shares during the period. Tower Research Capital LLC TRC grew its holdings in NantHealth by 778.8% during the third quarter. Tower Research Capital LLC TRC now owns 45,988 shares of the companys stock valued at $33,000 after purchasing an additional 40,755 shares during the period. Finally, Paragon Wealth Strategies LLC acquired a new position in NantHealth during the fourth quarter valued at approximately $38,000. 2.81% of the stock is owned by institutional investors and hedge funds.

About NantHealth

NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.

Read More: What does cost of debt say about a companys financial health?

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:

NantHealth (NASDAQ:NH) Stock Rating Lowered by ValuEngine - Riverton Roll